TDRG1 and plasma cell myeloma: H19 over-expression increases resistance to bortezomib by targeting miR-29b-39 to increase myeloid cell leukemia 1 (MCL-1) expression in multiple myeloma cells (Pan et al. 2019) and to cisplatin by targeting miR-106b-5p to enhance testis development-related 1 (TDRG1) expression in seminoma cells (Wei et al. 2018).